000119211 001__ 119211
000119211 005__ 20240228145426.0
000119211 0247_ $$2doi$$a10.1002/ijc.30433
000119211 0247_ $$2pmid$$apmid:27632639
000119211 0247_ $$2ISSN$$a0020-7136
000119211 0247_ $$2ISSN$$a1097-0215
000119211 0247_ $$2altmetric$$aaltmetric:12030077
000119211 037__ $$aDKFZ-2017-00001
000119211 041__ $$aeng
000119211 082__ $$a610
000119211 1001_ $$0P:(DE-He78)f3e9a7a759be776f3bab6f8d76308c76$$aMaierthaler, Melanie$$b0$$eFirst author$$udkfz
000119211 245__ $$aPlasma miR-122 and miR-200 family are prognostic markers in colorectal cancer.
000119211 260__ $$aBognor Regis$$bWiley-Liss$$c2017
000119211 3367_ $$2DRIVER$$aarticle
000119211 3367_ $$2DataCite$$aOutput Types/Journal article
000119211 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660824911_27718
000119211 3367_ $$2BibTeX$$aARTICLE
000119211 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119211 3367_ $$00$$2EndNote$$aJournal Article
000119211 520__ $$aCirculating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan® Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.
000119211 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000119211 588__ $$aDataset connected to CrossRef, PubMed,
000119211 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b1$$udkfz
000119211 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000119211 7001_ $$0P:(DE-He78)ec311cea9d07f894e44d05a570e26e28$$aSurowy, Harald$$b3$$udkfz
000119211 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b4$$udkfz
000119211 7001_ $$aKnebel, Phillip$$b5
000119211 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang, Jenny$$b6$$udkfz
000119211 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$udkfz
000119211 7001_ $$0P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aBurwinkel, Barbara$$b8$$eLast author$$udkfz
000119211 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.30433$$gVol. 140, no. 1, p. 176 - 187$$n1$$p176 - 187$$tInternational journal of cancer$$v140$$x0020-7136$$y2017
000119211 909CO $$ooai:inrepo02.dkfz.de:119211$$pVDB
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3e9a7a759be776f3bab6f8d76308c76$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ec311cea9d07f894e44d05a570e26e28$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000119211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000119211 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000119211 9141_ $$y2017
000119211 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000119211 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119211 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119211 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119211 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000119211 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119211 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119211 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119211 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119211 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119211 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119211 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000119211 9201_ $$0I:(DE-He78)C080-20160331$$kC080$$lMolekulare Epidemiologie$$x0
000119211 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000119211 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x2
000119211 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000119211 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x4
000119211 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000119211 980__ $$ajournal
000119211 980__ $$aVDB
000119211 980__ $$aI:(DE-He78)C080-20160331
000119211 980__ $$aI:(DE-He78)C060-20160331
000119211 980__ $$aI:(DE-He78)C070-20160331
000119211 980__ $$aI:(DE-He78)C020-20160331
000119211 980__ $$aI:(DE-He78)G110-20160331
000119211 980__ $$aI:(DE-He78)L101-20160331
000119211 980__ $$aUNRESTRICTED